Overall, our findings proved the feasibility of targeting IL-17A to sensitize the ICIs therapy in MSS CRC and revealed the novel mechanism by which IL-17A promotes PD-L1 expression in CRC cells for the first time. The gene discussed is IL17A; the disease is colorectal carcinoma.